The cost and challenge of vaccine development for emerging and emergent infectious diseases
- PMID: 30342926
- PMCID: PMC7129672
- DOI: 10.1016/S2214-109X(18)30418-2
The cost and challenge of vaccine development for emerging and emergent infectious diseases
Comment on
-
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study.Lancet Glob Health. 2018 Dec;6(12):e1386-e1396. doi: 10.1016/S2214-109X(18)30346-2. Epub 2018 Oct 18. Lancet Glob Health. 2018. PMID: 30342925 Free PMC article.
References
-
- European Centre for Disease Prevention and Control Rapid risk assessment: Zika virus epidemic in the Americas: potential association with microcephaly and Guillain–Barré syndrome—10 December 2015. 2015. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publicat...
-
- Ledgerwood JE, Costner P, Desai N. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2011;29:304–313. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
